Gregory Piazza, Alex C Spyropoulos, Judith Hsia, Mark Goldin, William J Towner, Alan S Go, Todd M Bull, Stephen Weng, Concetta Lipardi, Elliot S Barnathan, Marc P Bonaca
BACKGROUND: COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection)...
June 20, 2023: Circulation